Text Resize

-A +A

Raising £5 million for an essential Bioresource in support of the ground-breaking Summit Study

Raising £5 million for an essential Bioresource in support of the ground-breaking Summit Study

UCL Hospitals Charitable Foundation is honoured to be working closely with Professor Sam Janes and the Lungs for Living team, fundraising in support of the exciting and pioneering Summit Study. The Summit Study, which is already underway, is being delivered by UCLH in close collaboration with UCL and GRAIL, Inc. (a US healthcare company focused on the early detection of cancer).

The Summit Study’s aims are to detect lung cancer early, and to develop a new blood test for the early detection of multiple cancer types, including lung cancer. Working with 50,000 people across London who have been identified as having the highest risk of lung cancer, chronic obstructive pulmonary disease and cardiovascular disease, the Summit Study is one of the largest trials of its kind in the world.

The Summit Study is seeking to put early screening for lung cancer on the national agenda. Taking place over a five year period, from 2019 – 2024, participants in the study will receive lung health checks and screening along with regular blood sample checks. Screening for bowel, cervical and breast cancer are routine in England currently, but screening for lung cancer is not. It is hoped that the data collected from these activities will inform and prove beyond doubt that early screening for lung cancer is the way forward. Currently and all too frequently, lung cancer diagnosis happens too late.

(Professor Sam Janes, Chief Investigator of the Summit Study, pictured above)

UCL Hospitals Charitable Foundation has been asked to fundraise £5 million to pay for the design and production of a Lung and Heart Bioresource that is essential to the Summit Study. The UCLH Lung and Heart Bioresource will be the critical ‘by-product’ of the Summit Study, providing a unique database for future research into the world’s three most fatal diseases and enabling a unique study of those individuals at highest risk of developing them. The funding will also help to cover the costs of running and operating the bespoke Bioresource, which needs to be incredibly powerful in order to store the vast amount of biological information that will be gathered from the 50,000 participants over the five years of the study.

UCL Hospitals Charitable Foundation is extremely proud to be involved in supporting the Summit Study and to be a part of this ground-breaking research, improving early detection rates of lethal diseases, and creating hope for the future.